Paper Details

  1. Home
  2. Paper Details

Palifermin for oral mucositis after intensive therapy for hematologic cancers.

Author: BensingerWilliam, BlazarBruce R, ChenMon-Gy, ElhardtDieter, EmmanouilidesChristos, GentileTeresa, HansenKeith, KewalramaniTarun, LeMaistreC Frederick, McCartyJohn, NogaStephen, SheaThomas, SpielbergerRicardo, StiffPatrick, SungEric C, WeisdorfDaniel, YanovichSaul

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Palifermin significantly reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effective treatment. We tested the ability of palifermin (recombinant human keratinocyte growth factor) to decrease oral mucosal injury induced by cytotoxic therapy. METHODS: This double-blind study comp...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa040125

データ提供：米国国立医学図書館（NLM）

Palifermin: A New Oasis for Oral Mucositis

The [hematologic] landscape is often fraught with challenges, and one of the most debilitating is oral mucositis, a painful inflammation of the mouth caused by intensive chemotherapy and radiotherapy. This study investigates the potential of palifermin, a recombinant human keratinocyte growth factor, to mitigate oral mucositis in patients with hematologic cancers. The researchers conducted a [double-blind, placebo-controlled trial] on 212 patients, comparing the effects of palifermin to placebo. The findings demonstrate the effectiveness of palifermin in reducing the severity and duration of oral mucositis, offering a potential new approach for managing this common side effect of cancer treatment.

A Promising New Approach to Oral Mucositis

The study reveals that palifermin significantly reduced the incidence and duration of oral mucositis in patients undergoing intensive therapy for hematologic cancers. This finding is significant, as it offers a potential solution for a condition that often causes significant pain and discomfort, impacting the patient's quality of life during treatment.

Navigating the Desert of Oral Mucositis

This research provides a glimmer of hope for patients facing oral mucositis. The development of palifermin offers a new approach for managing this challenging side effect, potentially improving the patient's experience during cancer treatment. As with any medication, it's crucial to discuss the potential benefits and risks with a healthcare professional before making any treatment decisions.

Dr.Camel's Conclusion

Palifermin, like a refreshing oasis in the desert of oral mucositis, offers a potential solution for managing this common side effect of cancer treatment. The study demonstrates its effectiveness in reducing the severity and duration of mucositis, potentially improving the quality of life for patients during this challenging time. As with any new therapy, continued research is essential to further refine its use and optimize patient outcomes.

Date :
  1. Date Completed 2004-12-30
  2. Date Revised 2022-04-20
Further Info :

Pubmed ID

15602019

DOI: Digital Object Identifier

10.1056/NEJMoa040125

Related Literature

Article Analysis
・Effective treatment of tongue disorders
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.